The problem with approvals is that nobody in the market (including the FDA) trust Nader, and so they have to be absolutely certain that LL works before granting any sort of EUA or approval.

If we had a more credible CEO, the FDA would have more confidence in the data and provide more flexibility for allowances, (and obviously the stock price would be higher).

Trust in the science.